Rockefeller Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Rockefeller Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,591	Closed	-$14K	–	2755
2020 Q1	$14K	Hold	3,591	–	–	﹤0.01%	1646
2019 Q4	$18K	Buy	+3,591	New	+$19K	﹤0.01%	1443

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Rockefeller Capital Management's PGNX Position: Q2 2020 in Review

Rockefeller Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 3,591 shares — an estimated $14K sold.

Rockefeller Capital Management first reported a position in PGNX in Q4 2019 and held it in 2 quarters. The position peaked at $18K in Q4 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Rockefeller Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Rockefeller Capital Management sold 3,591 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $14K.
Rockefeller Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q4 2019 and held it in 2 quarters.
Rockefeller Capital Management's Progenics Pharmaceuticals Inc position peaked at $18K in Q4 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Rockefeller Capital Management's 13F filing for Q2 2020, filed 12 Aug 2020.